The mAbs were specific for lubricin since they did not cross-react with other synovial fluid constituents from patients with camptodactyly-arthropathy-coxa vara-pericarditis syndrome (CACP), who genetically lack this protein. This evidence concerns the gene PRG4 and camptodactyly-arthropathy-coxa vara-pericarditis syndrome.